Updates on the ELIANA trial for acute lymphocytic leukaemia in young patients
Dr Stephen Grupp talks to ecancer at ASH 2018 about the latest analysis of the ELIANA trial.
He describes how tisagenlecleucel continues to show durable remissions in paediatric and young patients with relapsed or treatment-resistant acute lymphocytic leukaemia.
Dr Grupp says that the take home message is that there are patients that are going to have long term disease control just with the CAR T therapy.
Watch his press conference here.
Read more about this work here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
-
Category
No comments found